sunitinib teva 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula - sunitinib
sunitinib teva 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib pharmascience 12,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 12,5 mg / 1 kapsula
sunitinib pharmascience 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula
sunitinib pharmascience 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula
odomzo
sun pharmaceutical industries europe b.v. - sonidegib difosfat - karcinom, bazalna celica - antineoplastična sredstva - odomzo je indiciran za zdravljenje odraslih bolnikov z lokalno napredovalim karcinomom bazalnih celic (bcc), ki niso primerni za kurativno kirurgijo ali radioterapijo.
lusmose 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
glukoza braun 100 mg/ml raztopina za infundiranje
b. braun melsungen ag - glukoza - raztopina za infundiranje - glukoza 100 g / 1000 ml - ogljikovi hidrati